|
|
 |
|
Viewing report
|
|
|
|
Market and Product Forecasts: Systemic Lupus Erythematosus - Benlysta approval kicks off new era in lupus treatment
Datamonitor, Aug 2011, Pages: 38
With its first-to-market status and an additional subcutaneous formulation in the pipeline, Datamonitor forecasts Benlysta to achieve and maintain market dominance over the next 10 years. Datamonitor forecasts four additional products to launch over the next 10 years, significantly altering the lupus market, and reaching sales of over $4bn in the US and five major EU markets by 2020.
Features and benefits
- Access The patient-based SLE market forecast in the US and five major EU markets, with transparent methodology and clear assumptions.
- Understand what will drive uptake of Benlysta, and how it will be positioned in the market as other products gain approval.
- Increase understanding of lupus market dynamics, and which factors will lead to commercial success.
- See which products Datamonitor forecasts to launch over the next 10 years, and how each subsequent launch will shape the market.
Highlights
- The April 2011 survey of 108 rheumatologists in the US suggests that there will be high uptake of Benlysta in moderate to severe patients, and some off-label use in mild patients. Datamonitor forecasts Benlysta to reach peak sales of $2.9bn in the US and five major EU markets in 2015, after which some share will shift to new products.
- Datamonitor forecasts five novel products to gain approval during the forecast period, the first of which is the newly launched Benlysta. By 2020 these products will account for the majority of the lupus market, and together will see sales of over $4bn in the US and five major EU markets.
- Based on primary research and discussions with key opinion leaders, Datamonitor forecasts that the SLE market will reach over $2.7bn in the US by 2020 (67% of total US and 5EU SLE sales). The EU forecast is dampened by the expectation of lower launch prices, and slower uptake of targeted therapies, resulting from higher cost restrictions.
Your key questions answered
- How do rheumatologists in the US plan to use Benlysta now that it has achieved US approval?
- How will Benlysta’s position be impacted by additional product launches over the next 10 years?
- Which attributes will lead to success as the lupus market sees competition grow for the first time?
- How will the US and EU markets compare to each other, and what will lead to higher growth in the US?
|
|
|
|
